Patients' Perspective of Medication Adherence in Chronic Conditions : A Qualitative Study by Pagès Puigdemont, Neus et al.
ORIGINAL RESEARCH
Patients’ Perspective of Medication Adherence
in Chronic Conditions: A Qualitative Study
Neus Page`s-Puigdemont . Maria Anto`nia Mangues . Montserrat Masip .
Giovanna Gabriele . Laura Ferna´ndez-Maldonado . Sergi Blancafort .
Laura Tuneu
Received: June 2, 2016 / Published online: August 9, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: About 50% of patients do not
take their long-term therapy for chronic
conditions as prescribed. Many studies have
centered on patients’ adherence to a specific
treatment or single conditions, but few have
taken all chronic conditions into consideration
from a patient’s perspective. This study aims to
explore factors that impact on drug compliance
and to identify strategies to improve this from
the perspective of patients with at least one
chronic condition.
Methods: Patients were recruited by healthcare
professionals from a hospital pharmacy, four
community pharmacies, patient associations,
and a primary care center in Barcelona. Five
focus groups were conducted (N = 36).
Conversations were audiotaped and transcribed
verbatim to allow qualitative analysis.
Results: Study subjects were aged 39–90 years
(mean 65 years) and the mean number of
comorbidities per patient was 2.3 (range 1–7).
The main modifiers of therapeutic conduct
were: patients’ health beliefs,
patient–prescriber relationships, and patients’
motivation and perception of illness control.
Study participants wanted greater participation
in decision-making concerning their health and
increased education about their illness and
medication. They also wanted individualized
healthcare that took their preferences and
personal and emotional issues into account.
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0AE4F06044A472AD.
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-016-0394-6)
contains supplementary material, which is available to
authorized users.
N. Page`s-Puigdemont (&)  M. A. Mangues 
M. Masip  L. Tuneu
Pharmacy Department, Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain
e-mail: npages@santpau.cat
N. Page`s-Puigdemont  M. A. Mangues  L. Tuneu
PhD Programme in Pharmacy, University of
Granada, Granada, Spain
M. A. Mangues
CIBER de Bioingenierı´a, Biomateriales y
Nanomedicina (CIBER-BBN), Barcelona, Spain
G. Gabriele  L. Ferna´ndez-Maldonado 
S. Blancafort
Fundacio´ Salut i Envelliment, Universitat Auto`noma
de Barcelona, Barcelona, Spain
G. Gabriele
Department of Sociology, Faculty of Economics and
Business, University of Barcelona, Barcelona, Spain
Adv Ther (2016) 33:1740–1754
DOI 10.1007/s12325-016-0394-6
Conclusion: Our results highlight how the
patient–prescriber’s relationship and factors such
as health beliefs, motivation and perception of
illness control impact on medication adherence
in chronic patients. Future interventions to
optimize adherence to treatment should focus
on shared decision-making and more extensive
health education.
Funding: Celgene Corporation.
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INTRODUCTION
Background
Medication adherence is a complex and
dynamic behavior that has been linked to
many aspects, such as socio-economic status,
the healthcare team and the healthcare system,
condition-related factors, therapy-related
factors, and patient-related factors [1–3]. It has
been estimated that about 50% of patients do
not take their long-term therapy for chronic
conditions as prescribed [1, 2, 4]. Such
non-adherence to medication is a major public
health problem. It has significant negative
consequences on both patients and providers,
such as loss of treatment effectiveness and
increases in healthcare costs [5].
Consequently, in view of the increasing
prevalence of chronic diseases, there is a clear
need to tackle medication non-adherence. In
Catalonia, as in many other regions in
developed countries, the prevalence of chronic
conditions is growing rapidly. Updated
demographic data shows that 38% of its
population has at least one chronic condition
and this percentage reaches 82.8% of people
over 75 years old [6].
The topic of medication adherence has been
largely reviewed through qualitative and
quantitative studies meaning a large number
of risk factors that play a role as barriers or
facilitators for medication adherence have been
identified. However, many studies have
centered on patients’ adherence to a specific
treatment or single conditions [7–13], but few
have taken all chronic conditions into
consideration from a patient’s perspective
[14, 15]. Due to the increasing burden of
chronic illness and prevalence of patients with
comorbidities, it is important to study
medication adherence not only in patients
with single conditions, but also with
coexisting chronic diseases.
To better understand medication adherence
and design interventions to improve it, it can be
useful to examine health behaviors. No single
theory can explain medication non-adherence
adequately since each one has its own
advantages and disadvantages. A conceptual
framework developed by combining aspects
from various theories can provide a better
understanding of this topic. Communicative
theories consider that an equal relationship
between patient and physician can improve
adherence. However, a change in adherence
behavior is not guaranteed since these theories
do not take into consideration patients’
attitudes and beliefs [16]. From the cognitive
perspective, there are some theories such as the
health belief model and the theory of reasoned
action that focus on behavior change and
consider that patients’ attitudes, beliefs, and
expectancies of outcomes are major
determinants of health behaviors including
medication adherence [17, 18]. Furthermore,
these theories suggest that patients act in the
way most likely to achieve positive health
outcomes according to their beliefs. The
common sense self-regulatory model proposes
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that individuals form cognitive representations
of ‘‘illness representation’’ through five
dimensions: causality, consequences,
controllability, identity, and timeline [19].
According to this theory, medication
adherence is based on a patient’s cognitive
factors and planning. This theory assumes that
people are active, self-regulating problem
solvers.
To gain insight into what factors act as a
barriers or facilitators of medication adherence
from a holistic approach and what
interventions may enhance patients’ health
behaviors to adherence conducts, it may be
useful to perform qualitative research.
Objective
As part of a larger project on medication
adherence, we conducted a qualitative study
to explore factors that impact on drug
compliance and to identify strategies to
improve it from the perspective of patients
with at least one chronic condition in the city
of Barcelona.
METHODS
Setting
The study took place in within a regional health
area at a tertiary hospital in the city of
Barcelona (Catalonia, Spain). Through a
literature review, we identified the most
interesting key informants for a first approach
to the study subject and to help in the design of
the discussion guide to conduct focus groups.
Consequently, we conducted eight
semi-structured interviews to a primary care
physician, a primary care nurse, a community
pharmacist, a member of the Spanish
Adherence Observatory, and four patients with
varying levels of medication adherence. They
helped identify the dimensions to be discussed
during focus group development. We chose
focus group methodology because this
technique enables discovering variety within a
population, in other words, obtaining a broad
range of views on a specific topic over a
relatively short period of time as opposed to
in-depth interviews [20]. Furthermore, group
interaction allows participants to clarify and
explore common perspectives.
The study protocol was approved by the
ethics committee of Hospital de la Santa Creu i
Sant Pau and was in accordance with the 1964
Helsinki declaration and its later amendments.
Informed consent was obtained from all
individual participants included in the study.
Patient Recruitment and Conduction
of Focus Groups
The inclusion criteria for participating in the
focus groups were patients receiving medication
for one or more chronic diseases. We excluded
patients \18 years old, patients with cognitive
impairment, patients with uncontrolled mental
conditions, and patients with no chronic
disease. We used a purposive and theoretical
sampling strategy and applied the purposeful
selection as an initial starting point, to study
examples that represent the phenomenon of
interest and, ultimately, to facilitate
comparison of emerging conceptual categories
and theory. Patients fulfilling eligibility criteria
were recruited by healthcare professionals
(co-investigators and collaborators of the
study) from a hospital pharmacy, four
community pharmacies, patient associations,
and a primary care center in Barcelona. Study
subjects did not receive any economic
compensation for their participation.
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The objective was to have 6–12 participants
for each focus group. We divided the groups as
much as possible into gender and level of
comorbidity. Further to this, there were two
participants that turned up in the focus group
with their partner that also had the role of
caregiver. As they also met inclusion criteria,
the members of the investigation team
considered that their point of view could be
useful and could enrich the discussion as they
were both patient and caregiver. The reason to
split up groups into these two variables was to
determine if a comparative assessment into a
wider spectrum of pathologies could help
determine the impact of gender factors and
complex comorbidity towards adherence. As
well as this, we also conducted a mixed group
to determine whether there were speech
divergences between male and female
participants.
Focus group sessions were conducted by
two members of the research team and lasted
for about 2 h or until saturation of responses
was reached. One member acted as a
moderator and asked open-ended questions
(see Appendix 1 in the supplementary
material) while the other member took
detailed notes during each group discussion.
All focus group sessions were audiotaped and
transcribed verbatim.
Study Analysis
The research team fragmented the texts of the
audiotapes, coded passages and performed
inductive categorization. Recurring themes
and discourse divergences were identified.
When the investigators had a complete study
overview, they met for discussion to reach a
consensus on emerging themes and made a
thematic content analysis.
Patients’ quotations were translated from
Catalan or Spanish into English by a native
speaker.
RESULTS
Sixty-three people were contacted to participate
in the study. Sixteen declined to take part in the
study and 13 were not located when organizing
focus groups. Finally, 36 people took part in five
focus groups (19 females, 17 males) between
December 2014 and February 2015. Study
subjects were aged 39–90 years (mean 65 years)
and the mean number of comorbidities per
patient was 2.3 (range 1–7). Participants’
conditions are shown in Table 1.
Below, we present a brief review that offers
some insight into what life with chronic
conditions involves, and how patients’
adherence perception is affected by its
constructs. We structured the results of the
focus groups into three major topics: patients’
health beliefs, patients’ health experiences, and
patients’ health behaviors related to medication
adherence and therapeutic attitudes. Table 2
lists a summary of the factors identified in our
study that impact on medication adherence
with representative quotations of study
participants.
Patients’ Health Beliefs
Patients with multimorbidity had the
perception of a main disease (that which most
affects their quality of life or threatens survival)
and the rate of medication adherence to treat it
was usually higher. On some occasions, patients
made decisions based on their own perceived
effect of the drug. The beliefs that affected
medication adherence and were expressed by
study participants were concerning drugs, drug
Adv Ther (2016) 33:1740–1754 1743
Table 1 Sociodemographic characteristics of focus groups participants
Participants Sex Age
(years)
Pathologies
Males with B2 comorbidities
Participant 1 M 81 Diabetes
Participant 2 M 46 AIDS and anxiety-depressive disorder
Participant 3 M 47 Ischemic heart disease and anxiety disorder
Participant 4 M 62 Parkinson
Participant 5 M 66 Colorectal cancer
Participant 6 Fa 44 Epilepsy
Participant 7 M 74 Diabetes and bipolar disorder
Males with[2 comorbidities
Participant 8 M 61 Chronic obstructive pulmonary disease and cardiac arrhythmia
Participant 9 M 71 Crohn’s disease, ischemic heart disease, and hypothyroidism
Participant 10 M 63 Prostate cancer, asthma, hypertension, cardiac arrhythmia, and hyperuricemia
Participant 11 Fa 71 Bronchiectasis, hypertension, and dyslipidemia
Participant 12 M 70 Parkinson
Participant 13 M 75 Parkinson disease, ischemic heart disease, diabetes, dyslipidemia, and depression
Participant 14 M 77 Hypertension, dyslipidemia and diabetes
Participant 15 M 72 Hypertension, hyperuricemia, anxiety, hiatal hernia, and past history of prostate cancer
and melanoma
Participant 16 M 63 Multiple myeloma and hematopoietic stem cell transplantation
Females with B2 comorbidities
Participant 17 F 41 Rheumatoid arthritis
Participant 18 F 59 Crohn’s disease and hypertension
Participant 19 F 79 Osteoporosis
Participant 20 F 40 Ankylosing spondylitis
Participant 21 F 39 Chronic myeloid leukemia and hypothyroidism
Participant 22 F 48 Chronic myeloid leukemia and chronic myalgia
Participant 23 F 76 Diabetes and hypertension
Participant 24 F 80 Diabetes
Females with[2 comorbidities
Participant 25 F 47 Chronic myeloid leukemia, anxiety-depressive disorder, ﬁbromyalgia and chronic fatigue
Participant 26 F 63 Parkinson disease and hypertension
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prescription, expectancies of treatment
effectiveness, and relative to
non-pharmacologic therapies.
Some study patients expressed beliefs that
led them to non-adherent conducts such as
considering drugs as chemicals or toxic
products and that they create a vicious cycle,
and a confidence in spontaneous organic
recovery without treatment.
Study participants showed a clear preference
not to take any medication, but they accepted it
with a certain feeling of defeat and resignation.
They considered that medication was often
prescribed routinely and that health
professionals did not contemplate possible
changes in health status so as to reduce drug
dose. They felt that in some way, a drug
prescription was a consequence of a lack of
time or resources for other types of treatments.
Some of them identified the pill burden as a
trend imposed by the health system as an
alternative to tailoring treatment.
Polymedicated patients wanted to prioritize
drugs regarded as essential for survival and to
maintain a good quality of life. From their point
of view, doctors should review their
medications regularly to see whether they are
still necessary. Patients also disagreed with the
responsibility transfer currently occurring in
healthcare; they felt disease was attributed as
their fault due to a lack of preventive measures
and self-care activities. Adherence behavior was
also influenced by patient’ expectancies of
treatment outcomes. Although, many study
subjects were conscious their illness could not
be cured, they expected an improvement in
their quality of life. Consequently, despite
initial skepticism and reluctance, if their
Table 1 continued
Participants Sex Age
(years)
Pathologies
Participant 27 F 90 Chronic leukemia, dyslipidemia, hypertension, diabetes, glaucoma, osteoporosis, and
gastric ulcer
Participant 28 F 69 Diabetes, hypertension and herniated disc
Participant 29 F 69 Hypothyroidism and diabetes
Participant 30 F 73 Parkinson disease, dystonia and pain
Mixed group
Participant 31 F 74 Post-traumatic stress
Participant 32 F 66 Epilepsy, stroke, and hypothyroidism
Participant 33 M 78 Ischemic heart disease and arthrosis
Participant 34 M 80 Stroke, hypertension, depression, and arthrosis
Participant 35 F 80 Arthrosis and renal failure
Participant 36 M 57 Renal failure and hypertension
F female, M male
a Two participants that turned up in the focus group with their partner also had the role of caregiver. As they also met
inclusion criteria, the members of the investigation team considered that their point of view could be useful and could
enrich the discussion as they were both patient and caregiver
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Table 2 Factors inﬂuencing therapeutic adherence identiﬁed from focus groups
Factors inﬂuencing
medications adherence
Patients’ quotations
Patients’ health beliefs
Perception of a main
disease
‘‘I’d give myself ten points for what I think is essential. Then I’d give myself a fail for what I
think is not essential’’
Beliefs about drug
prescription
‘‘I don’t comply because […] I don’t like being dependent on drugs’’
‘‘But there are other things they give you and that could be avoided. And no, not necessarily
take them for life’’
‘‘I also understand one thing: the doctor has a determined number of minutes to visit each
patient. In my case, psychological or psychiatric treatment or whatever would make sense for
my anxiety, but this is unthinkable. So they give you pills and, well, they keep you alive’’
‘‘Or maybe if they’re for life, instead of ten, you could take just ﬁve, ﬁnding a balance, but not
this tendency that seems like they have to ﬁll us with tablets’’
Beliefs about drugs and
illness
‘‘If you go on giving your body pills, it gets lazy’’
‘‘It’s like an addiction in the end, a complete dependence on drugs’’
‘‘I frankly, I think I’m poisoning myself with the drugs I´m taking’’
‘‘As everything is OK, I’ve even decided to try to stop it. […] And I understand that the disease
in the same way that the organism becomes sick, possibly it generates for recovery’’
Expectancies of
treatment outcomes
‘‘I know that if I take them [drugs], I feel good for sure’’
‘‘I hope to become an old lady in good health, as far as possible, and I know this is possible
thanks to drugs’’
‘‘I’m very reluctant to take any medication’’
‘‘For me, taking a treatment is like a defeat’’
Conﬁdence in
non-pharmacologic
treatments
‘‘If I found a doctor who suggested I try natural things, I could take less medication, because the
less I take, the better’’
‘‘It’s not just about whether alternative therapies can work or not, but I consider them as
complementary, not as a substitute’’
Patients’ health experiences
Prescriber–patient
relationship
‘‘As I’m very skeptical regarding neurologists, I’m cutting down the medication on my own’’
‘‘They don’t manage to get the patients to accept their part in the responsibility towards their
illness because in fact they take the responsibility’’
‘‘Maybe they need to spend ﬁve or ten minutes more to explain it to the patient […]. They
should not say: take this by Royal Decree’’
‘‘Feeling worse on leaving the consulting room than when you went in is the worst thing that
can happen. […] I think that treatment, medication and the relationship with the doctor are
very related’’
‘‘I’ve noticed things that weren’t normal and nobody explained this could happen. When you
don’t know what is happening to you […], of course, you distrust the doctor, the treatment
and the whole thing’’
‘‘I consider they’re very, very good professionals, but not when it comes to attention to the
patient’’
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Table 2 continued
Factors inﬂuencing
medications adherence
Patients’ quotations
Lack of emotional
support during medical
visits
‘‘We need more emotional support, not only physical support to give us pills or tests, but to
listen to the patient’’
‘‘There is an emotional component [in the pathophysiology of diseases] and sometimes it’s
dealt with and sometimes it´s not. In my case, it has been treated, and I can say that’s not just
necessary, it’s essential’’
‘‘I’d like to ﬁnd something more centered on the person, […] taking the person as a whole into
consideration’’
Patients’ autonomy ‘‘They opened a door for me that was fantastic. Not long ago you could only get this treatment
at the hospital, but now they say you can self-administer with a [subcutaneous] pen. […]
This has given me a lot more autonomy. It’s very different to spending the whole day coming
for treatment’’
‘‘It creates stress regarding work because you have to come to the hospital […]. So it’s a worry
and slows down your career’’
Patients’ perception of
disease control
‘‘Results don’t coordinate with what I take and what I do, and that makes me feeling nervous.
When I do a lot of sacriﬁce, I think: why?’’
‘‘The only thing that helps is knowing you are doing the right thing, that the disease is
controlled and you can lead a more or less normal life in spite of difﬁculties’’
Treatment characteristics ‘‘I have to take my medication one hour before lunch. If you’re out at night, you have to
calculate what time you’ll ﬁnish eating to calculate two hours’’
‘‘We don’t like being tied to a clock’’
Patients’ education ‘‘I want to know what I’m taking, why, what can happen and how it works. If there isn’t any
communication or information, you reach this conclusion: I’m not taking anything or I’ll
decide to stop it on my own’’
‘‘There is a lack of explanation of why you are being given that and what its effects are’’
Social support ‘‘Contact with people is one of the things that has helped me most’’
‘‘In my case, it would probably have helped me more knowing some other young person who
was epileptic. We would have felt rejected but together the situation wouldn’t have been so
lonely’’
‘‘A sick person gives himself what gives himself, and it seems that we [our society] impose to
follow a normal life at one hundred percent at all levels, though your body doesn’t respond’’
Patient’ health behaviors
Patients’ motivation ‘‘It’s useful to know you’re doing well’’
‘‘I take an antidepressant and I need to ﬁght, go outside, walk and do exercise. If three or four
days go by without me doing anything, I feel a little unﬁt and downhearted’’
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perception of their health status was good, their
trust in treatment was solid.
Although this was not a general opinion,
some participants commented on the possible
use of non-pharmacologic therapies. They
called these therapies complementary or
alternative depending on their confidence in
drugs. In some cases, the use of these therapies
was due to the subjective perception of drug
ineffectiveness and worsening of patient’s
quality of life.
Patients’ Health Experiences
The vast majority of study patients highlighted
the importance of the prescriber–patient
relationship. Patients’ trust in treatment could
vary depending on how they perceived the
prescriber’s attitude, especially in the initial
phases. Once mistrust was established, patients
were more likely to adopt skeptical attitudes
and non-adherent behaviors. Study participants
also pointed out the persistence of a
paternalistic model in the doctor–patient
relationship, known to be one of the main
barriers for patients to acquire responsibility for
their medication. They considered that
specialists had excellent clinical skills, but
lacked empathy towards patients. They also
felt a lack of therapeutic negotiation during
medical visits. In other words, patients wanted
to take some responsibility for their medication
under guidance of their physicians so some of
them considered therapeutic alliance a good
strategy to empower them.
Study patients especially appreciated a
treatment that could increase their autonomy.
They stated that when suffering from a chronic
illness the conciliation between medication and
their daily life influences therapeutic
adherence, especially in patients with low
comorbidity because of constant journeys to
healthcare centers. Patients also worried about
the impact of treatment on their professional
careers and family life.
In our study population, patients’ perception
of disease control appeared to motivate
medication adherence especially in patients
with high comorbidity. Body-listening, related
to the response of symptoms, was an important
part of this process, the ‘guiding light’ through
which it is possible to determine if the patient’s
treatment experience is good or must be
changed. Each participant faced multiple and
diverse challenges in order to balance the
prescribed regimen with physical and
psychosocial wellbeing whilst trying to
maintain quality of life. If treatment duration
was long and if patients did not perceive
therapeutic effectiveness their motivation
Table 2 continued
Factors inﬂuencing
medications adherence
Patients’ quotations
Patient’ attitudes ‘‘I take ﬁfteen different drugs […]. These ﬁfteen drugs give me a good quality of life, which is
what I’ve been always looking for […]. Because I accept that my illnesses will never get
better. As long as they stay the same though I don’t care’’
‘‘I take a very mild medication but my basic problem is that my wife has Alzheimer’s disease. I
ﬁght constantly for her but sometimes I forget to take my medication, because she comes ﬁrst’’
‘‘If I don’t need it I try not to take much. […] When I feel OK, I think: well, save it, keep it.
And I leave it’’
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could decrease and thus their adherence to
treatment. This was especially significant in
those patients suffering from several
comorbidities. Furthermore, treatment
characteristics such as dosage form, pill burden
and presence of adverse effects could modify
therapeutic conduct. Those treatments that
affect physical appearance (for instance,
increasing body weight) were reported by
some female participants to be causes of
non-adherence. Therapeutic complexity was
also identified as a cause of non-intentional
non-adherence by patients with polypharmacy
and high level of comorbidity.
Study participants also stressed the
importance of patient’s education and claimed
that more complete information would
improve therapeutic adherence. Most patients
said that a lack of knowledge about how drugs
work and their adverse effects increased their
fear of the nature of the drugs and their distrust
in medicine. As a result, information was
identified as a central element that allows
patients to deal better with their illness.
Patients took great value from explanations
given by health professionals as to how their
drugs worked as this helped to increase their
confidence in the treatment. Generally
speaking, patients showed a clear interest in
being involved in decision-making throughout
the therapeutic process if they received
adequate information.
Family and social support were very
important for many patients because they
helped in illness control. This support was
expressed in terms of accompaniment and not
helping in the administration of drugs.
Sometimes this support came from patients in
similar situations. Contrary to the majority, one
participant reported that today’s society
expected chronic patients to lead a normal life
even if their body did not allow them to.
Patient’ Health Behaviors
In this study, we identified three attitudes to
therapy: responsibility, prevention, and defeat.
The attitude of responsibility was expressed by
some female patients and by a need to have a
more proactive role in the management of their
health status. We also observed that when a
patient is also a caregiver, this attitude is
dominated by surveillance of the other
person’s medication adherence rather than
that of self. Many other patients showed a
prevention attitude that was strongly linked to
a desire to prevent future complications and to
maintain a good health status. This was more
common in women, and also in men with
polypharmacy or with high functional
impairment. Patients with this attitude also
tended to have a more active role in their own
care. Only few patients (those with AIDS and
epilepsy) had a defeatist attitude and this was
determined by the high level of social
stigmatization associated with these diseases
that led to not accepting the disease. This
attitude might account for the lack of
adaptation to therapeutic routine and the
commitment and the self-sacrifice needed for
following a treatment. Consequently, it could
lead to a suboptimal adherence.
In our study, collaborating actively to
achieve a better health status appeared to
generate greater security among patients.
Participants with healthy lifestyles and habits
tended to have adequate conduct towards
medication. Therefore, patients’ motivation
could enhance medication adherence.
Suggestions for Improving Medication
Adherence
Participants were also asked what helped them
to follow a treatment or improve medication
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adherence (Table 3). Most of the suggestions
were centered on improving patients’ education
and the relationship or the attention they
received from their prescriber. Participants also
complained about the little attention given to
mental health status in medical visits. They
sought greater clinical support concerning
emotional aspects and would like a holistic
approach, taking their preferences and family
context into account.
DISCUSSION
This study was motivated by the need to
understand chronic patients’ perspectives
about medication adherence. Knowing why
patients do not adhere to their treatments is
important for promoting adherence and
modifying the therapeutic regimen according
to their needs. Living with a chronic disease
encompasses multiple and complex behaviors
that patients must incorporate in their daily
routine and are determined by multiple factors
and modifiers. From this perspective, the
individual experience of adherence can be
understood as a continual evaluation by the
patient in terms of assessing the effectiveness of
the prescribed treatments in recovering their
normal daily life after disease onset. Treatment
process was related by participants as
continuous in time but a dynamic experience.
In other words, a personal experience that
varies according to the individual’s disease and
therapeutic process experience. Long-term
treatment is sometimes perceived by chronic
patients as a burden and loss, but on other
occasions as an opportunity to recover health
status and improve quality of life.
In our study, separating some focus groups
by gender and level of comorbidities meant
investigators were able to find some differences.
Until now, some research linked female gender
to a better adherence conduct [21–26], whereas
other studies suggested the opposite [27, 28]
and some other studies found no relationship
between gender and therapeutic adherence
[29, 30]. Our results showed that some female
patients took both a responsible and
preventative attitude, whereas this was absent
in men with the exception of those with
polypharmacy or high functional impairment.
For a patient with multiple comorbidities,
treatment over a longer duration was
perceived as worse, if it was not accompanied
by good clinical outcomes, than in a patient
with few conditions. This could lead to
non-adherence behavior. In contrast, patients
with few comorbidities were more concerned
about the conciliation of personal life than with
the duration of the treatment due to the
constant follow-up at healthcare centers.
Our research allowed us to identify several
modifiers of therapeutic conduct. The most
important modifiers for our patients were:
their health beliefs, the patient–prescriber
relationship, their motivation, and their
perception of illness control. However, there
were other factors involved in medication
adherence identified such as: patients’ fears,
patients’ education about treatment, family and
Table 3 Patients’ recommendations for improving
medication adherence
Therapeutic alliance
Being able to discuss with clinicians about treatment
options (shared decision-making)
Taking patients’ preferences into consideration when
prescribing a treatment
Paying more attention to mental health status during
medical visits
Holistic approach
Doctors should revise the patient therapeutic regimen
more often (tailoring the treatment)
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social support and patients’ personality (or
attitudes).
Patients’ beliefs about treatment are the
starting point of adherence and
non-adherence conduct. Beliefs and misbeliefs
influence both intentional and unintentional
adherence. On many occasions, the pattern of
therapeutic non-compliance in our participants
responded to health beliefs of overmedication,
pharmacological dependence, or disease
non-acceptance. Several participants also
recognized that certain situations triggered a
non-compliant conduct towards treatment: a
perceived lack of satisfactory results following
initial expectations, a fear of side effects, and
emotional tiredness from high pill burden.
Cognitive theories such as health belief model
and the theory of planned behavior assume that
if patients are provided with the logical
understanding of the benefits and risks of
taking medications, they will be better
adherent with the medications. Consequently,
health professionals need to engage with
chronic patients and communicate with them
regarding their health beliefs and provide them
with the adequate information about their
illness and treatment in order to increase
positive health results.
Subjects also sought a therapeutic balance
between the impossibility to cure their illness,
the dosage schedule, and their quality of life.
Due to this, treatment effectiveness has been
expressed as a search for the best match
between the right dosage and patient’s
expectations. Managing patients’ fears and
tailoring drug treatment to patients’ needs and
preferences during medical visits might
improve adherence to medication as some
patients reported.
Other factors involved in medication
adherence that emerged from this study and
coincide with numerous other studies were
confidence towards prescribers and the
patient–prescriber relationship [31, 32]. The
greater the confidence in the prescriber, the
greater the confidence in treatment. Many
patients wanted more complete information
and education from healthcare professionals so
as to be more involved in their own treatment.
They would like to change the paternalistic
model in healthcare assistance for a model
where they could negotiate their treatment
and the goals to achieve with their prescriber.
This topic of therapeutic alliance has been
largely studied in the field of psychotherapy
and many studies indicate that it plays a major
role as a good predictor of clinical outcome [33].
It helps both healthcare professionals and
patients to work together effectively. The
literature has also described the relationship
between good medication adherence and
therapeutic alliance. However, most studies to
date have been mainly performed in psychiatric
conditions like schizophrenia and bipolar
disorder [34, 35].
Many participants also stressed their dislike
of drugs being prescribed routinely and stated a
lack of emotional support during medical visits
in our healthcare system. For this reason, they
expressed the need for a holistic approach to
achieve health attention more centered to
person. This aspect is related to
patient–prescriber communication and this
relationship could explain why the number of
people who trust in complementary and
alternative medicines is increasing [36].
Patients with high comorbidities aimed not
to cure their disorder but to improve their
quality of life. When patients had a greater
perception of control of their disease, quality of
life and side effects, there was a greater
tendency to follow a correct therapeutic
conduct. Some patients complained of the
discipline required to follow a treatment. This
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can lead to a non-adherent conduct if they do
not perceive positive outcomes.
Limitations
The main limitation of this study is its
qualitative nature that does not allow the
results to be generalized. However, this was
not a purpose of the study since we wanted to
explore and to obtain rich and detailed
information about modifiers of medication
adherence in our health area. With this
information, we want to later design and
conduct a survey to determine the impact of
the factors identified in this qualitative research
in a wider and representative sample of chronic
patients.
Although this was a relatively adherent
population, as this was a qualitative study it
can be an advantage that study participants had
a common reality to avoid a polarization during
discussion that would have prevented from
advancing the discussion. Furthermore, many
participants expressed a good adherence
conduct when it referred to following a drug
treatment, but not when they had to change
their diet or exercise habits. And we know that
for reaching positive health outcomes in some
conditions, it is as important to engage in drug
treatment as it is a change in a patient’s
lifestyle.
In addition, all participants lived in an urban
area and none of them were immigrants, which
possibly influenced beliefs and opinions related
to therapeutic adherence.
CONCLUSIONS
Patients’ health beliefs, patient–prescriber
relationships, and patient’s motivation and
perception of illness control are important
modifiers of therapeutic adherence in our
study population from a regional health area
in Barcelona. Therapeutic alliance, shared
decision-making and better education about
their illness and treatments appear to be the
main strategies to improve medication
adherence in patients with chronic diseases.
PRACTICAL IMPLICATIONS
This study helps to understand patients’
attitudes and feelings towards their chronic
medication and illustrate that future
interventions to improve medication
adherence should focus on therapeutic alliance
and reinforcement of patient education. The
factors identified in this study will be the basis
to design a survey about what factors impact on
medication adherence in a wider sample of
patients affected by chronic conditions in the
same regional health area using a quantitative
approach.
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